In this video, Simulations Plus explains how to examine data and utilize advanced graphing tools within the platform. Key features include managing spreadsheet columns, creating custom tabs, and visualizing molecular properties through various chart types.
ADMET Predictor® Tutorial Series: Calculating Properties
In this video, we explore the core functionality of calculating chemical and biological properties. It covers selecting specific models, adjusting pH settings, and configuring multi-threading to maximize processing speed.
ADMET Predictor® Tutorial Series: MedChem Designer
In this video, we provide an interactive tutorial on using MedChem Designer to edit, create, and save chemical structures. You will also learn how to calculate ADMET properties directly within the designer and import structures from online resources like DrugBank.
ADMET Predictor® Tutorial Series: Working with Files
In this video, we demonstrate how to open chemical structure files and import external property data. You will also see how to save progress using proprietary XDK session files.
Integrating Diverse Clinical Data into a Single Virtual Population with Thales™
As the complexity of drug development increases, researchers need quantitative systems pharmacology (QSP) models that incorporate virtual populations and can capture data spanning numerous clinical trial
Prediction of the Lurasidone–Posaconazole Drug–Drug Interaction Using Physiologically Based Pharmacokinetic Modeling
Lurasidone is an atypical antipsychotic drug that metabolized by cytochrome P4503A4 (CYP3A4). Posaconazole is a triazole antifungal agent known to inhibit CYP3A4activity.
Metabolic Profiling and Detoxification of Eupalinolide A and B in Human Liver Microsomal Systems
Eupalinolide A (EA, Z-configuration) and Eupalinolide B (EB, E-configuration) are cis-trans isomeric sesquiterpenoid monomers isolated from Eupatorium lindleyanum DC. (Asteraceae).
QST Modeling Using BIOLOGXsym and Mechanistic Toxicity Data from a Biomimetic Liver Microphysiology System Predicts Increased Susceptibility to Nivolumab-Mediated Hepatotoxicity in MASLD Patients
Immune checkpoint inhibitor-related hepatotoxicity is a significant clinical concern
Integrated QSAR-ML and QST Modeling for Early Mechanistic Prediction of Clinical Hepatotoxicity Across Multiple Drug Classes
Drug-induced liver injury (DILI) is a major cause of drug attrition, often undetected until latestage clinical trials.
QST Modeling Using BIOLOGXsym™ Informed by Liver Microphysiology Data Predicts Biologics Induced Liver Injury and Enhanced Susceptibility in MASLD
Drug development has grown to include biologic treatments that address a range of unmet medical needs.
Simulations Plus Convenes Industry and Regulatory Leaders to Define Responsible AI in MIDD
Expert panel at the 2026 ASCPT Annual Meeting brings together leaders with industry and regulatory experience to explore practical, accountable AI implementation
Development of a Quantitative Systems Toxicology Model to Predict Drug-Induced Liver Injury in Pediatrics
Drug-induced liver injury (DILI) is an underrecognized cause of pediatric liver disease which accounts for almost 20% of pediatric acute liver failure cases, and is a major reason for liver transplantation in the USA [1].
Prospective Physiologically Based Pharmacokinetic Modeling Predictions of First-in-Patient Study PK: Examples and Application
The examples shown here are intended to provide an update on the accuracy of the method for prospective predictions.
A Pediatric Pbpk Model of Atropine Gel To Predict Atropine Levels in Children With Neurological Disorders After Administration to Oral Cavity
Sialorrhea, or excessive salivation, is a chronic and serious problem in children with cerebral palsy (CP) and neurodevelopmental disorders.[1–5] Sialorrhea occurs in up to 60% of children with CP...
Automated Concentration-QT data preparation, model selection and reporting in R
Since the publication of the ICH E14 guidance in 2015, QT interval prolongation as-sessment can be carried out with a concentration-QTc modeling approach as part of single- or mul-tiple- dose escalation studies, instead of conducting a thorough QT/QTc study.
mlxDesignEval: A novel R package for design evaluation based on MonolixSuite, and its comparison to popED and PFIM
Designing clinical trials to support population PK/PD modeling requires careful choices of sampling times, number of subjects, dose groups and other trial features to
ensure precise parameter estimation - with low relative standard errors [1].
Developing Biosimilars: How to Design PK and PD Similarity Studies Using Modeling & Simulation
Biosimilar development is crucial to making lifesaving treatments more affordable and accessible to patients—and researchers are under increasing pressure to reduce cost and time without compromising scientific rigor
GPX™ Tutorial Series: Introduction to Reprise Licensing
In this video we'll be talking about Introduction to Reprise Licensing.
GPX™ Tutorial Series: Injectables Intramuscular
In this video we'll be talking about Injectables Intramuscular.
GPX™ Tutorial Series: Injectables Subcutaneous
In this video we'll be talking about Injectables Subcutaneous.